Navigation Links
Affitech Acquires Pharmexa's Diabody Technology
Date:10/28/2008

OSLO, Norway, October 28 /PRNewswire/ -- Affitech AS, the human therapeutic antibody company, today announced that it had acquired the full rights to the innovative diabody technology originally owned by Pharmexa A/S, a leading Danish immunotherapeutic and vaccine company. Also known as bi-specific single chain antibodies, diabodies are recombinant antibody-like proteins whose unique attributes make them attractive candidates for a variety of therapeutic applications. The acquisition follows an exclusive license of the diabody IP that Affitech obtained in 2007 from Pharmexa to carry out certain non-clinical GLP compliant studies, as well as sub-licensing arrangements with third parties.

Affitech CEO Martin Welschof commented:

"This is a key strategic move for Affitech AS, since this diabody technology complements our existing antibody discovery platform perfectly. We are delighted to have this technology under our total ownership, which will benefit both our proprietary programs and our collaborations with pharma and biotech companies. In addition we will continue to seek actively sublicensing arrangements with third parties."

Editors notes

Affitech AS is a privately held human therapeutic antibody discovery and development company with headquarters and R&D facilities in Oslo, Norway and its US subsidiary in the San Francisco Bay Area. The Company's current disease focus is oncology and it utilizes two discrete but unique approaches for the discovery of fully human antibodies - (i) Molecule Based Antibody Discovery, and (ii) Cell Based Antibody Discovery. Molecule Based Antibody Discovery involves proprietary PhagemidScreeN and AffiScreeN(TM) technologies and uses validated targets for discovery purpose. Cell Based Antibody Discovery utilizes CBAS(TM) technology, which is a "reverse-screening" approach for discovering antibodies and their cognate targets from disease-specific cells. CBAS(TM) is also applicable to discovering antibo
'/>"/>

SOURCE Affitech AS
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
2. Affitech Appoints Dr. Keith McCullagh as Chairman
3. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
4. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
5. Neogen Acquires Kane Enterprises
6. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
7. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
8. United BioSource Acquires Interest in Leading Adaptive Design Technology Service Provider
9. NSF International Acquires David Begg Associates
10. United BioSource Acquires Caro Research, Leader in Simulation Modeling
11. Respironics Acquires Apollo Light Systems, Inc., Expands into Circadian Rhythm Device-Based Therapy Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... Aug. 19, 2014 A Geisinger researcher on ... for a Centers for Disease Control and Prevention (CDC) ... public health concern. Joseph Boscarino , ... of a team of researchers nominated for the Centers ... Science Award for Data Methods and Study Design. ...
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... - ARIUS Research Inc., (TSX:,ARI), a biotechnology company ... today announced that David Young, MD, President and,Chief ... Chinese Global,Financial Forum. Dr. Young will present on ... available prior to and following his presentation at ...
... DuPont Chairman and,CEO Charles O. Holliday, Jr., today told ... the world to keep pace with the rapid,growth in ... "Biotechnology is the most powerful tool available to secure ... holds the promise,to deliver the world more, higher quality ...
... Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ... company, today announced preliminary financial results from,the ... updated its financial,outlook for the full year ... the,release of Boston Scientific Corporation,s (BSC) third ...
Cached Biology Technology:ARIUS to present at Chinese Global Financial Forum 2Biotechnology Needed to Help Meet Growing Global Needs for Food, Feed, Fuel and Materials, DuPont Chairman & CEO Says at World Food Prize 2Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 2Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 3Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 4Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 5Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 6Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 7Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 8Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 9Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 10Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook 11
(Date:8/20/2014)... -- Bay Area Lyme Foundation, which aims to make ... applauds new research published in an upcoming issue of ... Diseases . The findings show that ticks that ... the year, making the threat of Lyme disease year-round. ... of Public Health (CDPH) Vector-borne Disease Section and University ...
(Date:8/20/2014)... who have suffered concussions ready to return to action? ... high school athletes who head back on the field ... regression in their abilities to simultaneously walk and do ... changes in their balance and/or altered walking speed, was ... 12 had returned to activity in less than a ...
(Date:8/20/2014)... Virginia Tech,s Wu Feng has built upon a National ... in the Cloud" program, and synergistically complemented it with ... the Air Force on "big computing" for mini-drones and ... Institutes of Health on "big data" for the life ... aspects from each grant, he was able to tell ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4
... Virtually all babies in the U.S. have their heels ... for genetic testing. These "heel stick" tests identify rare ... more disorders are added to the screening ?many states ... on the rise. In the June issue of Pediatrics, ...
... of their parents may give birds a preference for ... more exactly match those of their parents. Such learned ... traits and strong morphological differences between sexes ?phenomena seen ... reported by Carel ten Cate, Machteld Verzijden and Eric ...
... sub-Saharan Africa, according to the World Health Organization, and ... achieved limited success. But what if a vaccine against ... of Africa ?chancroid ?was relatively easy to develop and ... , That may be the case, according to researchers ...
Cached Biology News:Newborn screening can cause unnecessary parental stress 2Newborn screening can cause unnecessary parental stress 3Zebra finch males prefer females with exaggerated maternal traits 2Vaccine shown effective against chancroid 2Vaccine shown effective against chancroid 3
Hepatocyte Differentiation Environment...
High voltage electrophoresis power supply...
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
... Drummond Scientific has a long and ... microinjection apparatus. Several years ago we ... displacement microdispenser was being modified to ... unit by redesigning the microdispenser to ...
Biology Products: